0001209191-19-033219.txt : 20190529 0001209191-19-033219.hdr.sgml : 20190529 20190529165212 ACCESSION NUMBER: 0001209191-19-033219 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190516 FILED AS OF DATE: 20190529 DATE AS OF CHANGE: 20190529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shendelman Shoshana CENTRAL INDEX KEY: 0001775490 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 19862684 MAIL ADDRESS: STREET 1: C/O APPLIED THERAPEUTICS, INC. STREET 2: 340 MADISON AVENUE, 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10173 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 340 MADISON AVENUE STREET 2: 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10173 BUSINESS PHONE: 212-220-9319 MAIL ADDRESS: STREET 1: 340 MADISON AVENUE STREET 2: 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10173 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2019-05-16 2019-05-20 0 0001697532 Applied Therapeutics Inc. APLT 0001775490 Shendelman Shoshana C/O APPLIED THERAPEUTICS, INC. 340 MADISON AVENUE, 19TH FLOOR NEW YORK NY 10173 1 1 1 0 President and CEO Common Stock 2019-05-16 4 C 0 88397 A 88397 I See Footnote Series A Preferred Stock 2019-05-16 4 C 0 88397 0.00 D Common Stock 88397 0 I See Footnote Each share of Series A Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. These securities were unintentionally omitted from the Reporting Person's initial Form 4. The reportable securities are directly owned by Clearpoint Strategy Group LLC ("Clearpoint") of which the Reporting Person is the sole owner. The Reporting Person has sole voting and dispositive power over these securities. /s/ Jason Minio, Attorney-in-Fact 2019-05-29